Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

癌症和自身免疫中 COVID-19 感染的免疫调节

• 批准号: 10222320
• 负责人: Ignacio E. Sanz
• 金额: $ 79.55万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10222320
• 关键词: 2019-nCoV; ATAC-seq; Accounting; Acute; Age; Antibodies; Antibody Repertoire; Antiviral Response; Autoimmune Diseases; Autoimmune Process; Autoimmunity; B cell therapy; B-Lymphocytes; Biological Assay; COVID-19; COVID-19 vaccine; Cancer Patient; Cell Compartmentation; Cell physiology; Cells; Cessation of life; Clinical; Collaborations; Development; Disease; Equilibrium; Event; Fatal Outcome; Flow Cytometry; Generations; Heterogeneity; Human; Immune; Immune Tolerance; Immune response; Immunoglobulin-Secreting Cells; Immunologic Memory; Immunologics; Incidence; Individual; Infection; Interferons; Knowledge; Life; Longevity; Malignant Neoplasms; Measures; Mediating; Memory; Memory B-Lymphocyte; Molecular; Monoclonal Antibodies; Mus; Outcome; Pathogenesis; Pathogenicity; Pathologic; Pathology; Pathway interactions; Patients; Phase; Phenotype; Plasma Cells; Population; Regulation; Respiratory Failure; Severities; Severity of illness; Systemic Lupus Erythematosus; TLR7 gene; Vaccination; Viral; Work; autoreactivity; clinical heterogeneity; immune checkpoint blockade; immune-related adverse events; immunoregulation; neutralizing antibody; novel; programs; response; standard of care; transcriptome sequencing

Abstract COVID-19 infection is greatly heterogenous. Individuals with underlying immune dysregulation, will have abnormal responses to COVID-19, thereby accounting for different short-term outcomes and memory formation. Specifically, emerging evidence indicates poor outcomes in autoimmune and cancer patients. We propose that autoimmune patients and severe COVID-19 infection will share an exacerbated pathological response while cancer patients with disease-associated or treatment-induced immune deficiency, will fail to mount a protective anti-viral response. Here, we shall interrogate the effector B cell response to SARS-CoV-2 to identify determinants of protective and pathogenic responses in HC and autoimmune subjects.

摘要